Diabetes Clinical Trials in Maryland

Showing 541-560 of 659 trials

Interferon-Alpha for Diabetes Mellitus Type 1

NCT00024518

This study will see if interferon-alpha given early in the disease can stop or slow the immune attack on insulin-producing cells. In addition, the study will examine the safety and efficacy of interferon-alpha (given by mouth) to protect beta cell function. Patients between 3 and 25 years of age with Type 1 Diabetes Mellitus less then six weeks may be eligible for this study. All study-related tests and medications at the NIH Clinical Center are provided at no cost.

Insulin-Dependent Diabetes Mellitus

The University of Texas Health Science Center, Houston57 participantsStarted Sep 2001

Bethesda, Maryland, United States • Saint Paul, Minnesota, United States • Kansas City, Missouri, United States +2 more locations

COMPLETEDPhase 317 miles

Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome

NCT00968708

The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.

Diabetes Mellitus, Type 2Acute Coronary Syndrome

Takeda5,380 participantsStarted Sep 2009

Birmingham, Alabama, United States • Dothan, Alabama, United States • Mobile, Alabama, United States +905 more locations

Interferon-Alpha for Diabetes Mellitus Type 1

Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome

Diabetes Trials in Other Cities

Use of INTEGRA™ Flowable Wound Matrix to Manage Diabetic Foot Ulcers

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure

Dapagliflozin DPPIV Inhibitor add-on Study

Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive

Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Alone

Fatty Acid Binding Protein 2 (FABP2) Ancillary Proposal

Markers and Mechanisms of Vascular Disease in Type II Diabetes

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes and Periodontal Therapy Trial

Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy

Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes

Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes

Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study

Other Conditions in Maryland